西那卡塞用于血液透析患者继发难治性甲状旁腺功能亢进的疗效观察(3)
[4] Kiss I，Kiss Z，Ambrus C，et al.Age-dependent parathomone levels and different CKD-MBD treatment practices of dialysis patients in Hungary--results from a nationwide clinical audit[J].BMC Nephrol，2013，14：155.
[5] Jadoul M，Albert JM，Akiba T，et al.Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study[J].Kidney Int，2006，70(7)：1358-1366.
[6] Geert J Behets，Goce Spasovski，Lulu R Sterling，et al.Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J].Kidney International，2015，87，846-856.
[7] Zitt E，Fouque D，Jacobson S H，et al.Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction[J].Clin Kidney J，2013，6(3)：287-294.
[8] Spiegel D M，McPhatter L，Allison A，et al.A computerized treatment algorithm trial to optimize mineral metabolism in ESRD[J].Clin J Am Soc Nephrol，2012，7(4)：632-639.
[9] Kakuta T，Tanaka R，Kanai G，et al.Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism？[J].Ther Apher Dial，2009，13(Suppl 1)：S20-S27.
[10] Palmer S C，Nistor I，Craig J C，et al.Cinacalcet in patients with chronic kidney disease：a cumulative meta-analysis of randomized controlled trials[J].PLoS Med，2013，10(4)：e1001436., 百拇医药(毕秀龙 叶丽萍 程卫 王金茹)
[5] Jadoul M，Albert JM，Akiba T，et al.Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study[J].Kidney Int，2006，70(7)：1358-1366.
[6] Geert J Behets，Goce Spasovski，Lulu R Sterling，et al.Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J].Kidney International，2015，87，846-856.
[7] Zitt E，Fouque D，Jacobson S H，et al.Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction[J].Clin Kidney J，2013，6(3)：287-294.
[8] Spiegel D M，McPhatter L，Allison A，et al.A computerized treatment algorithm trial to optimize mineral metabolism in ESRD[J].Clin J Am Soc Nephrol，2012，7(4)：632-639.
[9] Kakuta T，Tanaka R，Kanai G，et al.Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism？[J].Ther Apher Dial，2009，13(Suppl 1)：S20-S27.
[10] Palmer S C，Nistor I，Craig J C，et al.Cinacalcet in patients with chronic kidney disease：a cumulative meta-analysis of randomized controlled trials[J].PLoS Med，2013，10(4)：e1001436., 百拇医药(毕秀龙 叶丽萍 程卫 王金茹)